share_log

EyePoint Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

SEC ·  Jan 11 13:00

Summary by Futu AI

Ocumension Therapeutics, a director at EyePoint Pharmaceuticals, Inc., is set to sell 1,910,500 shares of common stock on 01/11/2024, with an aggregate market value of approximately $37,159,225. The shares were originally acquired on 12/31/2020 through a private placement by EyePoint Pharmaceuticals. This transaction follows a previous sale of 1,000,000 shares by Ocumension Therapeutics in the past three months, which grossed $19,510,637.
Ocumension Therapeutics, a director at EyePoint Pharmaceuticals, Inc., is set to sell 1,910,500 shares of common stock on 01/11/2024, with an aggregate market value of approximately $37,159,225. The shares were originally acquired on 12/31/2020 through a private placement by EyePoint Pharmaceuticals. This transaction follows a previous sale of 1,000,000 shares by Ocumension Therapeutics in the past three months, which grossed $19,510,637.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated